Abstract Number: 1410 • 2019 ACR/ARP Annual Meeting
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Μechanism of Αction in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Background/Purpose: TNF inhibitors are a common treatment for rheumatoid arthritis (RA), but there is no best practice for when a specific TNF inhibitor stops working1.…Abstract Number: 1445 • 2019 ACR/ARP Annual Meeting
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States
Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib,…Abstract Number: 1892 • 2019 ACR/ARP Annual Meeting
Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
Background/Purpose: The impact of immunosuppression on post-operative outcomes in rheumatoid arthritis (RA) has primarily been studied in patients undergoing joint replacement surgery. We aimed to…Abstract Number: 2011 • 2019 ACR/ARP Annual Meeting
Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)
Background/Purpose: Somatic mutations caused by reactive oxygen and nitrogen species in inflamed joints, have been implicated in the destructive nature of RA. Mutation analysis also…Abstract Number: 2209 • 2019 ACR/ARP Annual Meeting
Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls
Background/Purpose: Osteoporosis is a common disease whose prognosis can be seriously impacted by the development of fractures that lead to functional limitations and may even…Abstract Number: 2305 • 2019 ACR/ARP Annual Meeting
Multimorbidity May Worsen Fatigue in Patients with Rheumatoid Arthritis
Background/Purpose: Fatigue is a pervasive problem for many patients with rheumatoid arthritis (RA) that often persists despite treatment with effective disease-modifying therapies. Recent studies have…Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…Abstract Number: 2816 • 2019 ACR/ARP Annual Meeting
An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium
Background/Purpose: CD8 T cells represent nearly half of T cells in inflamed synovium from patients with rheumatoid arthritis (RA). Research to date has focused on…Abstract Number: 2906 • 2019 ACR/ARP Annual Meeting
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Background/Purpose: In rheumatoid arthritis (RA) disease outcomes have improved enormously in the last decades. Due to early initiation of therapy, a treat-to-target approach and a…Abstract Number: 47 • 2019 ACR/ARP Annual Meeting
Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl – Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity
Background/Purpose: Serum anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA) display reactivity to a variety of cit-autoantigens. Studies of human ACPA mAbs have revealed that…Abstract Number: 180 • 2019 ACR/ARP Annual Meeting
Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data
Background/Purpose: Comorbidities are associated with worse clinical outcomes among patients with rheumatoid arthritis (RA), as does seropositive disease. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide…Abstract Number: 250 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 55
- Next Page »